Drugs / MK-3415A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01241552 | Oct 2011 → Dec 2014 | Clostridium difficile colitis | Merck Sharp & Dohme LLC | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3415A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01241552 ↗ |
| Modality | Monoclonal antibody | “Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B” PMID 32376702 ↗ May 2020 |